EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities

Jia Li, Jiayu Duan, Chaoyang Hua, Shaokang Pan, Guangpu Li, Qi Feng iD, Dongwei Liu, Zhangsuo Liu

Burns & Trauma · 01.01.2024 · 12

DOI: 10.1093/burnst/tkae044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Burns & Trauma, online erschienen am 29.11.2024. Verfasst von Jia Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Nephrology, Zhengzhou University, the First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Middle Ring Road, Jinshui…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key R&D and Promotion Special Projects of Henan Province, Youth Talent Promotion Project of Henan Province, Higher Education Key Research Project of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute kidney injury (AKI), a common kidney disease in which renal function decreases rapidly due to various etiologic factors, is an important risk factor for chronic kidney disease (CKD). The pathogenesis of AKI leading to CKD is complex, and effective treatments are still lacking, which seriously affects the prognosis and quality of life of patients with kidney disease. Nanomedicine, a discipline at the intersection of medicine and nanotechnology, has emerged as a promising avenue for treating kidney diseases ranging from AKI to CKD. Increasing evidence has validated the therapeutic potential of nanomedicine in AKI; however, little attention has been paid to its effect on AKI for patients with CKD. In this review, we systematically emphasize the major pathophysiology of the AKI-to-CKD transition and summarize the treatment effects of nanomedicine on this transition. Furthermore, we discuss the key role of nanomedicine in the regulation of targeted drug delivery, inflammation, oxidative stress, ferroptosis, and apoptosis during the transition from AKI to CKD. Additionally, this review demonstrates that the integration of nanomedicine into nephrology offers unprecedented precision and efficacy in the management of conditions ranging from AKI to CKD, including the design and preparation of multifunctional nanocarriers to overcome biological barriers and deliver therapeutics specifically to renal cells. In summary, nanomedicine holds significant potential for revolutionizing the management of AKI-to-CKD transition, thereby providing a promising opportunity for the future treatment of kidney diseases.

Schlagwörter

Stichwörter der Autor:innen

Acute kidney injuryChronic kidney diseaseNanomedicineTreatment

Autor:innen und Institutionen

  • Research Institute of Nephrology, Zhengzhou University, the First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Middle Ring Road, Jinshui District, Zhengzhou 450000, P. R. China.
  • Traditional Chinese Medicine Integrated Department of Nephrology, the First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Middle Ring Road, Jinshui District, Zhengzhou 450000, P. R. China.
  • Henan Province Research Center For Kidney Disease, No. 1 Longhu Middle Ring Road, Jinshui District, Zhengzhou 450000, P. R. China.
  • Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, No. 1 Longhu Middle Ring Road, Jinshui District, Zhengzhou 450000, P. R. China.
  • Department of Urology, Henan Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, No. 33 Longhu outer Ring Road, Jinshui District, Zhengzhou 450000, P. R. China.

ORCID-Profile: Qi Feng

Förderung

  • Key R&D and Promotion Special Projects of Henan Province
  • Youth Talent Promotion Project of Henan Province
  • Higher Education Key Research Project of Henan Province
  • Henan Medical Science and Technology Research Program Joint Construction Project
  • Young Scientists Fund of the National Natural Science Foundation of China
  • Medical Science and Technology Research Project of Henan Province
  • Outstanding Young Scientists Fund of Henan Health Commission of the People’s Republic of China

Zitieren

APA

Li, J., Duan, J., Hua, C., Pan, S., Li, G., Feng, Q., Liu, D., & Liu, Z. (2024). Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities. Burns & Trauma, 12. https://doi.org/10.1093/burnst/tkae044

Vancouver

Li J, Duan J, Hua C, Pan S, Li G, Feng Q, et al. Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities. Burns & Trauma. 2024;12. doi:10.1093/burnst/tkae044

BibTeX
@article{Li2024,
  author = {Li, Jia and Duan, Jiayu and Hua, Chaoyang and Pan, Shaokang and Li, Guangpu and Feng, Qi and Liu, Dongwei and Liu, Zhangsuo},
  title = {Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities},
  journal = {Burns & Trauma},
  year = {2024},
  volume = {12},
  doi = {10.1093/burnst/tkae044}
}
Kostenlos starten →